Greenleaf Trust Has $4.79 Billion Holdings in Stryker Corporation $SYK

Greenleaf Trust lowered its holdings in shares of Stryker Corporation (NYSE:SYK) by 4.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,228,545 shares of the medical technology company’s stock after selling 709,525 shares during the quarter. Stryker comprises about 46.2% of Greenleaf Trust’s investment portfolio, making the stock its biggest position. Greenleaf Trust owned approximately 3.97% of Stryker worth $4,794,555,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. State Street Corp raised its holdings in Stryker by 2.1% during the fourth quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after buying an additional 311,507 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock valued at $2,571,357,000 after acquiring an additional 45,478 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Stryker by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after acquiring an additional 69,851 shares in the last quarter. Norges Bank bought a new position in shares of Stryker in the 4th quarter valued at approximately $1,822,272,000. Finally, Bank of America Corp DE acquired a new stake in Stryker in the 2nd quarter worth approximately $1,404,284,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target on the stock. Royal Bank Of Canada decreased their price objective on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Wolfe Research lowered shares of Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. Piper Sandler decreased their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. lowered their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $386.28.

Stryker Trading Up 2.9%

Shares of SYK stock opened at $331.32 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $127.08 billion, a P/E ratio of 34.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The firm’s fifty day simple moving average is $329.10 and its 200 day simple moving average is $331.47. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the prior year, the business earned $3.13 earnings per share. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insiders Place Their Bets

In other Stryker news, insider Dylan Bram Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 50,000 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the transaction, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This represents a 2.17% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 351,267 shares of company stock worth $118,197,701 over the last 90 days. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.